Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.52 USD | +3.17% |
|
+9.09% | -7.42% |
| 10:25am | Nordic stocks in North America, Ericsson fell 1.6% | FW |
| 01/07 | Nordic stocks in North America, AstraZeneca rose 1.3% | FW |
| Market Cap | 11TCr 1.76TCr 1.53TCr 1.41TCr 1.31TCr 2.49TCr 1,67200Cr 2.53TCr 17TCr 6.58TCr 82TCr 6.59TCr 6.45TCr 2,83200Cr | P/E 2026 * |
24.5x | P/E 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 13TCr 2.05TCr 1.8TCr 1.65TCr 1.54TCr 2.92TCr 1,95600Cr 2.96TCr 20TCr 7.7TCr 96TCr 7.71TCr 7.55TCr 3,31400Cr | EV / Sales 2026 * |
4.84x | EV / Sales 2027 * | 3.92x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | +3.17% | ||
| 1 week | +9.09% | ||
| Current month | +3.80% | ||
| 1 month | +19.56% | ||
| 3 months | +3.69% | ||
| 6 months | -10.39% | ||
| Current year | -7.42% |
| 1 week | 25.97 |  | 28.78 |
| 1 month | 24.08 | | 28.78 |
| Current year | 23.62 | | 35.43 |
| 1 year | 20.33 | | 35.43 |
| 3 years | 17.24 | | 42.72 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.17% | +9.09% | - | - | 1.76TCr | |
| +0.68% | +6.27% | +77.60% | +133.76% | 5.87TCr | |
| +2.32% | +5.89% | +76.81% | +99.20% | 5.39TCr | |
| +3.86% | +8.38% | -9.90% | -9.62% | 2.47TCr | |
| +4.30% | +6.82% | +13.60% | +428.91% | 2.42TCr | |
| +4.74% | +13.47% | +46.43% | +0.03% | 1.88TCr | |
| 0.00% | +16.74% | +171.12% | +355.99% | 1.63TCr | |
| +3.50% | +4.92% | +26.07% | +192.26% | 1.4TCr | |
| +6.72% | +20.94% | +51.67% | - | 1.39TCr | |
| +2.67% | +2.79% | +75.95% | +128.61% | 1.22TCr | |
| Average | +3.20% | +6.48% | +58.82% | +166.14% | 2.63TCr | |
| Weighted average by Cap. | +2.69% | +5.14% | +61.04% | +149.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.77TCr 424.47Cr 371.07Cr 341.01Cr 317.86Cr 602.9Cr 40TCr 612.04Cr 4.09TCr 1.59TCr 20TCr 1.59TCr 1.56TCr 68TCr | 3.25TCr 496.74Cr 434.25Cr 399.08Cr 371.98Cr 705.55Cr 47TCr 716.25Cr 4.79TCr 1.86TCr 23TCr 1.86TCr 1.82TCr 80TCr |
| Net income | 476.3Cr 73Cr 64Cr 59Cr 55Cr 103.55Cr 6.94TCr 105.12Cr 703.15Cr 273.35Cr 3.41TCr 273.65Cr 267.78Cr 12TCr | 702.99Cr 107.6Cr 94Cr 86Cr 81Cr 152.83Cr 10TCr 155.15Cr 1.04TCr 403.44Cr 5.04TCr 403.89Cr 395.22Cr 17TCr |
| Net Debt | 1.95TCr 298.81Cr 261.22Cr 240.06Cr 223.76Cr 424.42Cr 28TCr 430.85Cr 2.88TCr 1.12TCr 14TCr 1.12TCr 1.1TCr 48TCr | 1.25TCr 191.12Cr 167.08Cr 153.55Cr 143.12Cr 271.46Cr 18TCr 275.58Cr 1.84TCr 716.59Cr 8.95TCr 717.4Cr 701.99Cr 31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $28.52 | +3.17% | 14,14,977 |
| 01/26/01 | $27.64 | +0.62% | 14,50,434 |
| 30/26/30 | $27.47 | +5.57% | 25,73,567 |
| 29/26/29 | $26.02 | -0.38% | 20,29,457 |
| 26/26/26 | $26.12 | -0.08% | 17,78,429 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
